ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP73-18 Taft Hartley Third Party Administrators and Remote Processing Claims Delays
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2018
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2971 - 2980 လၢ 4030 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP37-17 APR-DRG and EAPG Grouper Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 14, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP4-16 Pre-Admission Notification Submissions on the Availity Web Portal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 05, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP98-18 Migration of Minnesota Health Care Programs Subscribers to Amerigroup Delayed to January 1, 2109
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 28, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP95-18 Provider Cost Data Update
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 28, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP82-18 Pharmacy Benefit Exclusion for Azedra (iobenguane I 131) Intravenous Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 28, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP86-18 Addition of Drug to the Calcitonin Gene-Related Peptide (CGRP) Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 14, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP70-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3) and Lanoxin (digoxin) Injection for Minnesota Health Care Programs Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP35-17 Implementation of New Utilization Management Platform
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 07, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP85-18 Pharmacy Benefit Update - New Drug-Related PA with QL Criteria: Pseudobulbar Affect (PBA)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2018